Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients

被引:358
作者
Jeppesen, PB
Sanguinetti, EL
Buchman, A
Howard, L
Scolapio, JS
Ziegler, TR
Gregory, J
Tappenden, KA
Holst, J
Mortensen, PB
机构
[1] Univ Copenhagen Hosp, Rigshosp, Dept Med CA2121, Gastroenterol Sect, DK-2100 Copenhagen, Denmark
[2] NPS Pharmaceut, Salt Lake City, UT USA
[3] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Chicago, IL 60611 USA
[4] Albany Med Coll, Div Gastroenterol & Nutr, Albany, NY 12208 USA
[5] Mayo Clin, Jacksonville, FL 32224 USA
[6] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA
[7] Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA
[8] Univ Copenhagen, Panum Inst, DK-2200 Copenhagen, Denmark
关键词
D O I
10.1136/gut.2004.061440
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Glucagon-like peptide 2 (GLP-2) may improve intestinal absorption in short bowel syndrome (SBS) patients with an end jejunostomy. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant GLP-2 analogue, prolongs the intestinotrophic properties of GLP-2 in animal models. The safety and effect of teduglutide were investigated in SBS patients with and without a colon in continuity. Methods: Teduglutide was given subcutaneously for 21 days once or twice daily to 16 SBS patients in the per protocol investigational group, 10 with end jejunostomy ( doses of 0.03 ( n = 2), 0.10 ( n = 5), or 0.15 ( n = 3) mg/kg/day), one with <50% colon in continuity ( dose 0.03 mg/kg/day), and five with >= 50% colon in continuity ( dose 0.10 mg/ kg/day). Nutrient balance studies, D-xylose tests, and intestinal mucosa biopsies were performed at baseline, on the last three days of treatment, and after three weeks of follow up. Pre-study fasting native GLP-2 levels were determined for the five patients with >= 50% colon in continuity. Results: Pooled across groups and compared with baseline, teduglutide increased absolute (+ 743 ( 477) g/day; p< 0.001) and relative (+ 22 ( 16)%; p< 0.001) wet weight absorption, urine weight (+ 555 ( 485) g/day; p< 0.001), and urine sodium excretion (+ 53 ( 40) mmol/day; p< 0.001). Teduglutide decreased faecal wet weight ( 2711 ( 734) g/day; p = 0.001) and faecal energy excretion ( 2808 (1453) kJ/day (-193 (347) kcal/day); p = 0.040). In SBS patients with end jejunostomy, teduglutide significantly increased villus height (+ 38 ( 45)%; p = 0.030), crypt depth (+ 22 ( 18)%; p = 0.010), and mitotic index (+ 115 ( 108)%; p = 0.010). Crypt depth and mitotic index did not change in colonic biopsies from SBS patients with colon in continuity. The most common side effects were enlargement of the stoma nipple and mild lower leg oedema. The improvements in intestinal absorption and decreases in faecal excretion noted after treatment had reversed after the drug free follow up period. A controlled study with a more robust design is ongoing in order to determine the optimal dosage of teduglutide for SBS patients to achieve the maximal effect and utility of this drug in clinical practice. Conclusion: Teduglutide, at three dose levels for 21 days, was safe and well tolerated, intestinotrophic, and significantly increased intestinal wet weight absorption in SBS patients with an end jejunostomy or a colon in continuity.
引用
收藏
页码:1224 / 1231
页数:8
相关论文
共 24 条
  • [1] AGA technical review on short bowel syndrome and intestinal transplantation
    Buchman, AL
    Scolapio, J
    Fryer, J
    [J]. GASTROENTEROLOGY, 2003, 124 (04) : 1111 - 1134
  • [2] Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
    Cheeseman, CI
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1997, 273 (06) : R1965 - R1971
  • [3] Basolateral D-glucose transport activity along the crypt-villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2
    Cheeseman, CI
    O'Neill, D
    [J]. EXPERIMENTAL PHYSIOLOGY, 1998, 83 (05) : 605 - 616
  • [4] Induction of intestinal epithelial proliferation by glucagon-like peptide 2
    Drucker, DJ
    Ehrlich, P
    Asa, SL
    Brubaker, PL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) : 7911 - 7916
  • [5] GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets
    Guan, XF
    Stoll, B
    Lu, XF
    Tappenden, KA
    Holst, JJ
    Hartmann, B
    Burrin, DG
    [J]. GASTROENTEROLOGY, 2003, 125 (01) : 136 - 147
  • [6] Structure, measurement, and secretion of human glucagon-like peptide-2
    Hartmann, B
    Johnsen, AH
    Orskov, C
    Adelhorst, K
    Thim, L
    Holst, JJ
    [J]. PEPTIDES, 2000, 21 (01) : 73 - 80
  • [7] Management of complications in patients receiving home parenteral nutrition
    Howard, L
    Ashley, C
    [J]. GASTROENTEROLOGY, 2003, 124 (06) : 1651 - 1661
  • [8] CURRENT USE AND CLINICAL OUTCOME OF HOME PARENTERAL AND ENTERAL NUTRITION THERAPIES IN THE UNITED-STATES
    HOWARD, L
    AMENT, M
    FLEMING, CR
    SHIKE, M
    STEIGER, E
    [J]. GASTROENTEROLOGY, 1995, 109 (02) : 355 - 365
  • [9] *IND LAB CAN INC, CBB330 IND LAB CAN I
  • [10] Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
    Jeppesen, PB
    Hartmann, B
    Thulesen, J
    Hansen, BS
    Holst, JJ
    Poulsen, SS
    Mortensen, PB
    [J]. GUT, 2000, 47 (03) : 370 - 376